BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX
BioCryst Pharmaceuticals stock price today
$8.21
+0.50
+6.49%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
BioCryst Pharmaceuticals stock price monthly change
+7.83%
month
BioCryst Pharmaceuticals stock price quarterly change
+7.83%
quarter
BioCryst Pharmaceuticals stock price yearly change
+24.56%
year
BioCryst Pharmaceuticals key metrics
Market Cap | 1.54B |
Enterprise value | 2.02B |
P/E | -6.3 |
EV/Sales | 7.47 |
EV/EBITDA | -14.08 |
Price/Sales | 5.86 |
Price/Book | -5.39 |
PEG ratio | 0.21 |
EPS | -1.06 |
Revenue | 355.39M |
EBITDA | -77.08M |
Income | -208.58M |
Revenue Q/Q | 34.87% |
Revenue Y/Y | 22.68% |
Profit margin | -91.24% |
Oper. margin | -54.81% |
Gross margin | 97.57% |
EBIT margin | -54.81% |
EBITDA margin | -21.69% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBioCryst Pharmaceuticals stock price history
BioCryst Pharmaceuticals stock forecast
BioCryst Pharmaceuticals financial statements
| Jun 2023 | 82.49M | -75.32M | -91.31% |
|---|---|---|---|
| Sep 2023 | 86.74M | -36.14M | -41.67% |
| Dec 2023 | 93.40M | -61.73M | -66.09% |
| Mar 2024 | 92.76M | -35.37M | -38.14% |
| Mar 2024 | 92.76M | -35.37M | -38.14% |
|---|---|---|---|
| Sep 2025 | 122.36M | -7.04M | -5.76% |
| Oct 2025 | 125.94M | -10.30M | -8.18% |
| Dec 2025 | 137.28M | -1.03M | -0.75% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 529885000 | 918.59M | 173.36% |
|---|---|---|---|
| Sep 2023 | -685518000 | 933.91M | -136.23% |
| Dec 2023 | 516960000 | 972.48M | 188.12% |
| Mar 2024 | 467892000 | 944.05M | 201.77% |
| Jun 2023 | -18.81M | -19.03M | 29.35M |
|---|---|---|---|
| Sep 2023 | -19.89M | 23.11M | 1.22M |
| Dec 2023 | -8.91M | -28.47M | -3.17M |
| Mar 2024 | -53.68M | 28.75M | -1.04M |
BioCryst Pharmaceuticals alternative data
| Sep 2023 | 531 |
|---|---|
| Oct 2023 | 531 |
| Nov 2023 | 531 |
| Dec 2023 | 531 |
| Jan 2024 | 531 |
| Feb 2024 | 531 |
| Mar 2024 | 536 |
| Apr 2024 | 536 |
| May 2024 | 536 |
| Jun 2024 | 536 |
| Jul 2024 | 536 |
BioCryst Pharmaceuticals other data
70.82%
-29.18%
of BCRX is owned by hedge funds
220
+21
126.85M
+8.98M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 183601 | 0 |
| Jun 2024 | 0 | 19987 |
| Dec 2024 | 0 | 7000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HUTSON NANCY J director | Common Stock | 7,000 | $7.54 | $52,780 | ||
Sale | MCKEE AMY E director | Common Stock | 8,600 | $6.32 | $54,352 | ||
Sale | SANDERS MACHELLE director | Common Stock | 4,689 | $6 | $28,134 | ||
Sale | HEGGIE THERESA director | Common Stock | 6,698 | $6.11 | $40,925 | ||
Purchase | LEVIN ALAN G director | Common Stock | 7,861 | $6.36 | $49,996 | ||
Purchase | ASELAGE STEVE director | Common Stock | 2,500 | $6.4 | $16,000 | ||
Purchase | HUTSON NANCY J director | Common Stock | 5,000 | $6.38 | $31,900 | ||
Purchase | MILANO VINCENT director | Common Stock | 15,000 | $6.25 | $93,750 | ||
Purchase | DOYLE ANTHONY officer: Chief Financial Officer | Common Stock | 36,300 | $5.57 | $202,191 | ||
Purchase | THACKRAY HELEN M. officer: Chief R&D Officer | Common Stock | 30,000 | $5.86 | $175,800 |
| Patent |
|---|
Application Filling date: 2 Sep 2021 Issue date: 30 Jun 2022 |
Application Filling date: 8 Apr 2020 Issue date: 26 May 2022 |
Application Filling date: 13 Jul 2021 Issue date: 31 Mar 2022 |
Application Filling date: 21 Oct 2021 Issue date: 10 Feb 2022 |
Grant Utility: Human plasma kallikrein inhibitors Filling date: 10 Apr 2020 Issue date: 25 Jan 2022 |
Grant Utility: Human plasma kallikrein inhibitors Filling date: 24 Mar 2020 Issue date: 21 Dec 2021 |
Grant Utility: Human plasma kallikrein inhibitors Filling date: 24 Mar 2020 Issue date: 7 Dec 2021 |
Grant Filling date: 16 Aug 2019 Issue date: 16 Nov 2021 |
Grant Filling date: 6 Feb 2020 Issue date: 14 Sep 2021 |
Grant Filling date: 1 May 2019 Issue date: 7 Sep 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 26 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Jon P. Stonehouse (1961) Chief Executive Officer, Pres & Executive Director | $1,120,000 |
| Dr. William P. Sheridan (1955) Chief Medical Officer & Senior Vice President | $786,970 |
| Dr. Yarlagadda S. Babu (1953) Chief Discovery Officer | $682,620 |
Dr. Helen M. Thackray FAAP, M.D. (1968) Chief R&D Officer | $55,000 |
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
BioCryst: Strong Opportunity For A Double With A Proven Therapy
BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely
Rezolute: Negative EV Opportunity Initiating A Phase 3 Ultra-Orphan Pediatric Study
The Big Short: 5 Stocks At Risk With High Short Interest
BioCryst's Commercialization Of Orladeyo: Risks Materializing, A Shorting Opportunity
BioCryst: Good Candidate For Buyout, But Not For Anything Else
BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo
-
What's the price of BioCryst Pharmaceuticals stock today?
One share of BioCryst Pharmaceuticals stock can currently be purchased for approximately $8.21.
-
When is BioCryst Pharmaceuticals's next earnings date?
Unfortunately, BioCryst Pharmaceuticals's (BCRX) next earnings date is currently unknown.
-
Does BioCryst Pharmaceuticals pay dividends?
No, BioCryst Pharmaceuticals does not pay dividends.
-
How much money does BioCryst Pharmaceuticals make?
BioCryst Pharmaceuticals has a market capitalization of 1.54B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.37% to 331.41M US dollars.
-
What is BioCryst Pharmaceuticals's stock symbol?
BioCryst Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "BCRX".
-
What is BioCryst Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BioCryst Pharmaceuticals?
Shares of BioCryst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BioCryst Pharmaceuticals's key executives?
BioCryst Pharmaceuticals's management team includes the following people:
- Mr. Jon P. Stonehouse Chief Executive Officer, Pres & Executive Director(age: 64, pay: $1,120,000)
- Dr. William P. Sheridan Chief Medical Officer & Senior Vice President(age: 70, pay: $786,970)
- Dr. Yarlagadda S. Babu Chief Discovery Officer(age: 72, pay: $682,620)
- Dr. Helen M. Thackray FAAP, M.D. Chief R&D Officer(age: 57, pay: $55,000)
-
How many employees does BioCryst Pharmaceuticals have?
As Jul 2024, BioCryst Pharmaceuticals employs 536 workers.
-
When BioCryst Pharmaceuticals went public?
BioCryst Pharmaceuticals, Inc. is publicly traded company for more then 31 years since IPO on 4 Mar 1994.
-
What is BioCryst Pharmaceuticals's official website?
The official website for BioCryst Pharmaceuticals is biocryst.com.
-
Where are BioCryst Pharmaceuticals's headquarters?
BioCryst Pharmaceuticals is headquartered at 4505 Emperor Boulevard, Durham, NC.
-
How can i contact BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals's mailing address is 4505 Emperor Boulevard, Durham, NC and company can be reached via phone at +91 98591302.
BioCryst Pharmaceuticals company profile:
BioCryst Pharmaceuticals, Inc.
biocryst.comExchange:
NASDAQ
Full time employees:
536
Industry:
Biotechnology
Sector:
Healthcare
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
4505 Emperor Boulevard
Durham, NC 27703
Durham, NC 27703
CIK: 0000882796
ISIN: US09058V1035
CUSIP: 09058V103
